Celularity, a birth-tissue regenerative biologics company, has announced an exclusive licensing agreement with a relatively new ophthalmic biotech company, DefEYE
Celularity has also executed an in-kind investment of $12M in the DefEYEs Series Seed Preferred Equity Round.
Proceeds from the funding round are expected to support the launch and expansion of decellularized biologic solutions for eye care. The planned product portfolio includes:
- Single- and tri-layer Decellularized Amniotic Basement Membrane (Biovance® and Biovance® 3L Ocular)
- Interfyl®, a flowable human connective tissue derived from the chorionic plate
- Collaborative research and development for future commercial products
The agreement grants DefEYE an exclusive sublicense to Celularity’s ophthalmic biologics portfolio, with Celularity serving as the exclusive contract manufacturer for these biologic solutions.
“This strategy fits into our objective of accessing new markets for our portfolio of commercial products,” said Robert J.Hariri, M.D., Ph.D., Celularity’s Chairman and CEO
DefEYE’s leadership team includes key members from Verséa Ophthalmics, and as part of the agreement, Celularity will have the right to appoint one member to DefEYE’s board of five directors.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
